Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 21

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 21
---

 number of our securities in the public market by our existing securityholders could cause the price of our Common Stock and Warrants 
 to fall.                                                                                                                             |

| ● | certain existing securityholders                                                                                                     
 purchased our securities at a price below the current trading price of such securities, and may experience a positive rate of return 
 based on the current trading price. Future investors in us may not experience a similar rate of return.                              |

| ● | we have incurred significant                                                                                                            
 losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve       
 or maintain profitability. Our independent registered public accountants have expressed substantial doubt as to our ability to continue 
 as a going concern.                                                                                                                     |

| ● | our business is highly                                                                                                             
 dependent on the success of our lead product candidate. If we are unable to advance clinical development, obtain approval of and   
 successfully commercialize our lead product candidate for the treatment of patients in approved indications, our business would be 
 significantly harmed.                                                                                                              |

| ● | our engineered CER-T cells                                                                 
 represent a novel approach to cancer treatment that creates significant challenges for us. |

| ● | our preclinical programs                                                                                                               
 may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals 
 or to commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.                    |

<div align='center'>3</div>

| ● | success in preclinical                                                                 
 studies or clinical trials may not be indicative of results in future clinical trials. |

| ● | manufacturing genetically                                                                                                              
 engineered products is complex and we, or our third-party manufacturers, may encounter difficulties in production. If we or any of     
 our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials 
 or our products for patients, if approved, could be delayed or prevented.                                                              |

| ● | if we are unable to advance                                                                                                      
 clinical development, obtain approval of and successfully commercialize our lead product candidate for the treatment of patients 
 in approved indications, our business would be significantly harmed.                                                             |

| ● | genetic engineering of                                                                                                            
 T cells to create CER-T cells is a relatively new technology, and if we are unable to use this technology in our intended product 
 candidates, our revenue opportunities will be materially limited.                                                                 |

| ● | we will depend on enrollment                                                                                                           
 of patients in our clinical trials for